Abstract:Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Science, Innovation and Universities, Spain by Consejería de Educación, Cultura y Deportes. Junta de Comunidades de Castilla-La Mancha. Background Phospholamban regulates SERCA2a pump activity by reducing its calcium affinity in the heart. Under β-adrenergic stimulation, protein kinase A (PKA) phosphorylates phospholamban attenuating its inhibitory effect on SERCA2a. The phospholamban mutation Arg 9 to Cys (R9C) was firstly identified in an American family with ventricular dilatation and premature death, and subsequently in a cohort of dilated cardiomyopathy patients in South Africa. Emerging evidence suggests that phospholamban R9C is a loss-of-function mutation with autosomal dominant inheritance. In vitro studies revealed that it enhances pentamer assembly by disulfide bridge formation, reducing the availability of phospholamban monomers to regulate SERCA2a. Purpose The present study aimed to investigate defects in Ca2+ handling and cardiac function of phospholamban R9C mutation in an in vivo zebrafish model. Methods We generated transgenic zebrafish lines overexpressing phospholamban wild-type (TgPLNwt) and phospholamban R9C (TgPLNR9C) in the heart of zebrafish. To measure calcium kinetics in 3 day-old larvae, TgPLNwt and TgPLNR9C fish were outcrossed with transgenic zebrafish lines expressing the fluorescent calcium biosensor mCyRFP1-GCaMP6f (TgRFP-GcaMP6f) and the bioluminescence calcium biosensor GFP-Aequorin (TgGA) in the heart. Results Overexpression of phospholamban wild-type and R9C did not alter the heart rate compared to sibling larvae, and no differences were observed in the upstroke and recovery time of the calcium transients. However, atrial and ventricular calcium transient amplitude were higher in TgPLNR9C larvae with respect to TgPLNwt larvae. Contractile force of the heart, assessed as the fractional shortening, increased in TgPLNR9C larvae compared to siblings and TgPLNwt. Furthermore, stroke volume and cardiac output were also higher in TgPLNR9C larvae. Bioluminescence experiments were performed to estimate the average calcium levels in the heart. We found that TgPLNR9C larvae showed higher calcium levels than sibling and TgPLNwt larvae. To evaluate the responsiveness to β-adrenergic stimulation, larvae were treated with the β-agonist isoproterenol. Calcium transient amplitude and contractile force increased in sibling and TgPLNwt larvae after treatment. However, this response was absent in TgPLNR9C larvae, suggesting that they were hyper-stimulated in basal conditions, displaying amplitude and contractile force similar to sibling and TgPLNwt larvae treated with isoproterenol. Conclusion TgPLNR9C larvae exhibited aberrant calcium handling in the heart with higher calcium levels and contractility, consistent with a lack of inhibition of SERCA2a. Consequently, TgPLNR9C larvae did not respond to β-adrenergic stimulation. These results were consistent with previous in vitro studies carried out in cardiomyocites infected with phospholamban R9C and highlighted the pathological defects of phospholamban R9C at early stages of the disease.

A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase

Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells.

A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids

Early consequences of the phospholamban mutation PLN‐R14del+/− in a transgenic mouse model

Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation

Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

Dysfunctional conformational dynamics of protein kinase A induced by a lethal mutant of phospholamban hinder phosphorylation

Human disease-causing mutations result in loss of leiomodin 2 through nonsense-mediated mRNA decay

Impaired autophagy mechanisms associated with phospholamban-R14del disease

A Novel Human Phospholamban Promoter Polymorphism in Dilated Cardiomyopathy Alters Glucocorticoid Nuclear Receptor Mediated Transcription Regulation

Recessive but damaging alleles of muscle-specific ribosomal protein gene RPL3L drive neonatal dilated cardiomyopathy

The phenotypic characteristic observed by cardiac magnetic resonance in a PLN-R14del family

Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro

Phospholamban p.Leu39* Cardiomyopathy Compared with Other Sarcomeric Cardiomyopathies: Age-Matched Patient Cohorts and Literature Review

Rescue of Cardiomyocyte Dysfunction by Phospholamban Ablation Does Not Prevent Ventricular Failure in Genetic Hypertrophy.

Cardiac Hypertrophy and Arrhythmia in Mice Induced by a Mutation in Ryanodine Receptor 2

Phenotyping calcium and contraction in a zebrafish model of phospholamban R9C mutation

Phospholamban mutations in human dilated cardiomyopathy